Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.
Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.
Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.
If left untreated, TTTS can have devastating consequences. Medical research indicates that:
TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.
Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.
Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.
Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:
Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.
Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.
Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.
According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.
When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.
Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.
Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."
Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.
Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.
The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.
Credit: AI image
The United States is not the only country to lose its measles elimination status this year. Mexico and Bolivia have also lost the status after the highly contagious virus continued spreading for more than 12 months, according to the Pan American Health Organization (PAHO).
The decision was formally announced on November 17, 2026 by PAHO's independent Regional Monitoring and Re-Verification Commission, which reviewed measles data from 47 countries and territories across the Americas.
The United States had maintained its measles elimination status since 2000, while Mexico and Bolivia had also previously interrupted sustained local transmission. The latest development marks a setback in efforts to control a disease that can be prevented through vaccination.
The announcement comes as measles cases continue to rise across the region. As of November 13, 2026, the Americas had reported 58,213 confirmed cases and 82 deaths, compared with 12,806 cases during the same period in 2025.
Also read: 112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC
According to PAHO, a country loses its measles elimination status when the same measles virus genotype and lineage circulates continuously within its borders for at least 12 months. This indicates that the virus has re-established endemic transmission rather than appearing only through isolated cases imported from other countries.
According to PAHO, the sustained transmission periods in the three countries began on different dates:
Losing elimination status does not mean that measles is spreading everywhere within these countries. It means that the same virus lineage has continued circulating locally for at least a year.
The Americas had previously lost its regional measles elimination status in November 2025, after Canada reported to have sustained transmission for more than 12 months. The region had first eliminated measles in 2016 and regained that achievement in 2024 after stopping transmission in Venezuela and Brazil.
Also read: US Loses Measles Elimination Status After 26 Years: What Does It Mean?
After PAHO's announcement, US Health and Human Services Secretary Robert F. Kennedy Jr and Centers for Disease Control and Prevention (CDC) Director Dr Erica Schwartz issued separate statements.
Kennedy said the administration would continue working to control outbreaks and restore the country's elimination status.
"We will stop measles outbreaks, protect American families, and work to regain U.S. measles elimination status," he said in a statement. He also expressed his support for vaccination, adding, "I continue to recommend MMR vaccination as the most effective way to prevent measles."
Kennedy attributed gaps in childhood immunisation to disruptions during the COVID-19 pandemic which affected routine vaccination programmes in the US and other countries.
He also said that approximately $100 million in additional CDC funding has been provided since August to strengthen measles prevention and outbreak response. The funding is intended to support state and local health departments, improve surveillance and help close vaccination gaps.
CDC Director Dr Schwartz said the loss of the designation would not change the agency's approach to controlling the disease.
"The measles elimination designation is not what protects Americans. Vaccination does. We know where transmission is occurring and we've invested $100 million in state and local health departments to reach those communities," she said.
"Losing a designation doesn't mean we abandon an evidence-based approach. It means we remain focused on stopping outbreaks."
Also read: RFK Jr's Vaccine Controversy: What His Samoa Trip Has To Do With 83 Measles Deaths
The latest PAHO figures highlight the scale of the resurgence. The region recorded more than four times as many confirmed measles cases by November 13, 2026 as during the corresponding period in 2025.
Mexico has reported more than 13,900 confirmed cases so far in 2026, the highest annual total since the 1989-90 epidemic. The US has recorded more than 5,400 cases and 10 deaths, its highest in more than 35 years. Bolivia has reported more than 100 cases.
Amid the resurgence, a CDC report has identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns. Nearly all the women were unvaccinated or had an unknown vaccination status.
Measles is among the most contagious infectious diseases. One infected person can transmit the virus to as many as 18 people who are susceptible to infection.
The disease typically causes fever, cough, a runny nose, red and watery eyes, followed by a characteristic skin rash. However, it can also lead to serious complications, including pneumonia, brain inflammation (encephalitis), blindness and death. It can also weaken the immune system for months after infection.
PAHO expects the US, Mexico and Bolivia to submit plans outlining how they plan to interrupt transmission and strengthen measles vaccination and surveillance.
The organisation has called on countries across the Americas to achieve and maintain at least 95% coverage with both doses of the measles vaccine.
The MMR vaccine, which protects against measles, mumps and rubella, remains the most effective way to prevent measles.
Credit: AI image
The US Food and Drug Administration (FDA) has granted approval to a new drug that could help patients with a rare and life-threatening genetic disorder live longer. The treatment, Lembaz (adrabetadex), is the first drug proven to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C (NPC).
Announced on November 17, 2026, the approval marks an important development for families affected by the rare disease, which causes progressive neurological damage and can significantly shorten life expectancy.
Lembaz is approved for adults and children weighing at least 7 kg (approximately 15 pounds) whose neurological symptoms began before the age of six. It is administered as an injection directly into the fluid surrounding the spinal cord, a procedure known as an intrathecal injection, every two weeks.
"For the first time, there is a treatment shown to help adults and children with this serious disease live longer," said Acting FDA Commissioner Kyle Diamantas.
The FDA's approval was based on data from 36 patients treated with Lembaz across three clinical studies. Their outcomes were compared to an external control group of patients who had not received the treatment.
The analysis found that patients who received Lembaz had a 55% lower risk of death compared to the control group.
The median overall survival was 8.5 years among patients treated with Lembaz compared to 4.9 years in the control group.
The benefit was observed regardless of whether patients were also receiving miglustat, another medicine used to manage NPC.
Also read: Childhood Obesity: Wegovy Cuts BMI By 10% In Children As Young As 6; What Are The Risks?
Niemann-Pick disease type C is a rare inherited disorder that affects the body's ability to process cholesterol and other fatty substances inside cells.
The condition is caused by changes in either the NPC1 or NPC2 gene. These genes produce proteins that help move cholesterol and other lipids within cells. When these proteins do not function properly, fatty substances accumulate inside cells, affecting organs like liver, spleen and brain. Over time, this causes progressive damage to the nervous system.
Patients may experience difficulties with movement, balance, coordination, speech and swallowing. Some may also face seizures, cognitive difficulties and problems controlling eye movements.
The disease affects approximately one in 150,000 people, according to the FDA. Its symptoms and severity can vary depending on when the disease begins.
Also read: 112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC
Infantile-onset NPC refers to cases in which neurological symptoms start before the age of six. These patients experience a more aggressive disease as they face rapid progressive neurological deterioration and a shorter life expectancy.
As the disease advances, children may gradually lose the ability to walk, speak and swallow independently. Difficulties with swallowing can also increase the risk of respiratory complications.
There is currently no cure for NPC, making treatments that can slow disease progression or improve survival important.
Lembaz contains adrabetadex, a cyclodextrin-based medicine made to address the underlying cholesterol processing defect in NPC.
In simple terms, the drug helps move cholesterol trapped inside cells, especially brain cells, so that it can be transported to areas where it is needed.
By targeting this underlying problem, the treatment aims to reduce the cellular damage that comes with the disease.
According to the FDA, hearing impairment, including permanent hearing loss, could be one of the side effects of Lembaz. Hence, patients must undergo hearing assessments before starting the drug and regularly throughout the course.
Other common side effects include balance and coordination problems, fatigue, vomiting, back pain, headache, fever, diarrhoea, nausea and cough.
Credit: AI Image
The US has lost its measles elimination status after 26 years, with Bolivia and Mexico also losing the designation, the Pan American Health Organization (PAHO) announced on Tuesday. The decision follows more than 12 months of continuous measles transmission in the US.
Amid the resurgence, a CDC-led report has identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns. Nearly all the women were unvaccinated or had an unknown vaccination status.
The actual number of infections among pregnant women may be higher. A separate CIDRAP News investigation based on state health department data identified at least 167 pregnant women infected in 2025 and 2026.
Also Read: What Happens After Measles Infection? The Hidden Risks That Can Last For Years
The CDC-led report, published in NEJM Evidence journal, found that 108 (96%) of the 112 cases occurred during outbreaks involving 50 or more cases.
Of the infected women, 110 (98%) had received no MMR vaccine doses or had an unknown vaccination status.
Twenty-six women (23%) were hospitalized for reasons unrelated to childbirth, while 11 (10%) developed pneumonia.
“Even though measles is an old disease, measles in pregnancy is an emerging area that we need to learn about,” said Michelle Barton, a professor at the Schulich School of Medicine & Dentistry at Western University.
Read More: Congenital Measles Reported In Pennsylvania For First Time In Decades: What Parents Should Know
The report recorded 21 pregnancy outcomes within 14 days of maternal rash onset: 19 live births and two pregnancy losses, including one miscarriage and one stillbirth.
Eight babies were born prematurely, and eight required admission to a neonatal intensive care unit (NICU).
The report noted that 13 babies had congenital measles and tested positive for the virus. Of these, six developed symptoms, including one with signs compatible with meningoencephalitis, a potentially life-threatening inflammation of the brain and surrounding membranes.
The authors said the outbreaks highlighted measles' risks to maternal and newborn health.
Many doctors and nurses treating these patients have never encountered measles, relying largely on medical training and professional guidelines to manage the infections.
The CDC recommends intravenous immunoglobulin as post-exposure prophylaxis for pregnant women without documented MMR vaccination or other evidence of immunity who are exposed to measles.
Newborns exposed to measles in the womb should also receive immunoglobulin at birth. Congenital measles can cause severe neurological complications, including subacute sclerosing panencephalitis (SSPE), a rare, progressive brain disorder.
The US is experiencing its highest measles burden in more than three decades. Since 2025, approximately 7,700 people have been infected and 13 have died, according to the figures cited in the report.
As of November 12, the CDC had confirmed 5,412 cases and six deaths in 2026. States had reported 10 deaths.
The rise in infections has coincided with declining vaccination rates and growing vaccine hesitancy. US Health Secretary Robert F. Kennedy Jr. has repeatedly questioned measles vaccine safety without scientific evidence supporting those claims.
The CDC said it would work to stop outbreaks and regain elimination status by supporting states and providing sustained national leadership.
"The measles elimination designation is not what protects Americans; vaccination does," CDC Director Erica Schwartz said.
© $2026 Times Horizon Private Limited